Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8567303 | 1.00 | NAMPT (0.46) | NAMPTNR1H2KDM1AMTNR1AMTNR1B | |
| SCHEMBL8567306 | 1.00 | NAMPT (0.46) | NAMPTNR1H2KDM1AMTNR1AMTNR1B | |
| SCHEMBL16385106 | 1.00 | NAMPT (0.46) | NAMPTNR1H2KDM1AMTNR1AMTNR1B | |
| SCHEMBL6410947 | 0.88 | NAMPT (0.46) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL15521240 | 0.86 | NAMPT (0.44) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL16384801 | 0.85 | NAMPT (0.43) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL15520515 | 0.85 | NAMPT (0.43) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL16353469 | 0.84 | NAMPT (0.42) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL16353534 | 0.84 | NAMPT (0.42) | NAMPTKDM1AMTNR1AMTNR1BBCHE | |
| SCHEMBL16353667 | 0.82 | NOTUM (0.47) | NAMPTKDM1ABCHEHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | claimed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | claimed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | claimed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | claimed |
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | disclosed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | disclosed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | disclosed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | disclosed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | disclosed |
| WO-2015004015-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | CYP2S1, PRMT3, ARGLU1 | NAMPT 1849/4885NR1H2 1702/4885KDM1A 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.